Biodexa Pharmaceuticals annual total assets
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Total Assets Growth & History (BDRX)
Biodexa Pharmaceuticals's total assets was £18.2M for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £18.2M | £3.4M | +23.00% |
| 2024 | 2024-12-31 | £14.8M | £4.2M | +40.20% |
| 2023 | 2023-12-31 | £10.5M | £5.0M | +90.81% |
| 2022 | 2022-12-31 | £5.5M | −£7.4M | −57.21% |
| 2021 | 2021-12-31 | £12.9M | £3.1M | +31.54% |
| 2020 | 2020-12-31 | £9.8M | −£21.1M | −68.22% |
| 2019 | 2019-12-31 | £30.9M | £10.5M | +51.12% |
| 2018 | 2018-12-31 | £20.4M | −£28.8M | −58.47% |
| 2017 | 2017-12-31 | £49.2M | −£7.5M | −13.17% |
| 2016 | 2016-12-31 | £56.7M | −£7.4M | −11.48% |
| 2015 | 2015-12-31 | £64.0M | — | — |
Biodexa Pharmaceuticals quarterly total assets
Q4.18
Q4.19
Q4.20
Q4.21
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | £18.2M | £3.4M | +23.00% |
| Q2 2025 | 2025-06-30 | £14.8M | £856,000 | +6.13% |
| Q4 2024 | 2024-12-31 | £14.8M | £4.2M | +40.20% |
| Q2 2024 | 2024-06-30 | £14.0M | £6.0M | +75.43% |
| Q4 2023 | 2023-12-31 | £10.5M | £5.0M | +90.81% |
| Q2 2023 | 2023-06-30 | £8.0M | — | — |
| Q4 2022 | 2022-12-31 | £5.5M | −£7.4M | −57.21% |
| Q4 2021 | 2021-12-31 | £12.9M | £3.1M | +31.54% |
| Q4 2020 | 2020-12-31 | £9.8M | −£21.1M | −68.22% |
| Q4 2019 | 2019-12-31 | £30.9M | £10.5M | +51.12% |
| Q4 2018 | 2018-12-31 | £20.4M | — | — |
Biodexa Pharmaceuticals total assets trends
Over the last five fiscal years, Biodexa Pharmaceuticals's total assets increased from £9.8M to £18.2M, a change of £8.4M. The latest reported quarter, Q4 2025, shows £18.2M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...